Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1462337 | 0.92 | GRIK1 (1.00) | GRIK1GRIK2 | |
| SCHEMBL3957527 | 0.88 | GRIK1 (1.00) | GRIK1GRIK2 | |
| SCHEMBL3962344 | 0.87 | GRIK1 (1.00) | GRIK1GRIK2 | |
| SCHEMBL6431068 | 0.87 | GRIK1 (1.00) | GRIK1GRIK2 | |
| SCHEMBL3962742 | 0.87 | GRIK1 (1.00) | GRIK1GRIK2 | |
| SCHEMBL3957387 | 0.86 | GRIK1 (1.00) | GRIK1GRIK2 | |
| SCHEMBL23831439 | 0.85 | GRIK1 (0.80) | GRIK1GRIK2 | |
| SCHEMBL3965616 | 0.85 | GRIK1 (1.00) | GRIK1GRIK2 | |
| SCHEMBL5950252 | 0.84 | GRIK1 (1.00) | GRIK1GRIK2 | |
| SCHEMBL6430905 | 0.83 | GRIK1 (1.00) | GRIK1GRIK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060069255-A1 | Novel aryl ureido benzoic acid derivatives and their use | NEUROSEARCH (DK) | 2006-03-30 | — | — | US | claimed |
| EP-1565429-A2 | ARYL UREIDO DERIVATIVES AND THEIR MEDICAL USE | NEUROSEARCH A/S (DK) | 2005-08-24 | — | — | EP | claimed |
| WO-2004046090-A2 | ARYL UREIDO DERIVATIVES AND THEIR MEDICAL USE | NEUROSEARCH A/S (DK) | 2004-06-03 | — | — | WO | claimed |
| US-7521480-B2 | Aryl ureido benzoic acid derivatives and their use | NEUROSEARCH (DK) | 2009-04-21 | — | — | US | disclosed |
| US-20060069255-A1 | Novel aryl ureido benzoic acid derivatives and their use | NEUROSEARCH (DK) | 2006-03-30 | — | — | US | disclosed |
| EP-1565429-A2 | ARYL UREIDO DERIVATIVES AND THEIR MEDICAL USE | NEUROSEARCH A/S (DK) | 2005-08-24 | — | — | EP | disclosed |
| WO-2004046090-A2 | ARYL UREIDO DERIVATIVES AND THEIR MEDICAL USE | NEUROSEARCH A/S (DK) | 2004-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069255-A1 | Novel aryl ureido benzoic acid derivatives and their use | GABRA5, GRIK5, GRM5 | GRIK1 24/4885GRIK2 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.